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A B S T R A C T   
The incidence of the novel coronavirus disease (COVID-19) outbreak caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) has brought daunting complications for people as well as physicians 
around the world. An ever-increasing number of studies investigating the characteristics of the disease, day by 
day, is shedding light on a new feature of the virus with the hope that eventually these efforts lead to the proper 
treatment. SARS-CoV-2 activates antiviral immune responses, but in addition may overproduce pro- 
inflammatory cytokines, causing uncontrolled inflammatory responses in patients with severe COVID-19. This 
condition may lead to lymphopenia and lymphocyte dysfunction, which in turn, predispose patients to further 
infections, septic shock, and severe multiple organ dysfunction. Therefore, accurate knowledge in this issue is 
important to guide clinical management of the disease and the development of new therapeutic strategies in 
patients with COVID-19. In this review, we provide a piece of valuable information about the alteration of each 
subtype of lymphocytes and important prognostic factors associated with these cells. Moreover, through dis-
cussing the lymphopenia pathophysiology and debating some of the most recent lymphocyte- or lymphopenia- 
related treatment strategies in COVID-19 patients, we tried to brightening the foreseeable future for COVID- 
19 patients, especially those with severe disease.   
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1. Introduction 
December 2019 will never be forgotten in the history of medicine, 
when an outbreak of pneumonia caused by the novel coronavirus (se-
vere acute respiratory syndrome coronavirus 2; SARS-CoV-2) sooner or 
later prompted the World Health Organization (WHO) to issue a public 
health warning emergency. Pneumonia, acute respiratory distress syn-
drome (ARDS), and multiple organ failure are the most important 
challenges that the virus induces in infected individuals. This is, in fact, 
the host immune responses against SARS-CoV-2 that holds a respectable 
share in the occurrence of these symptoms, rather than the virulence 
characteristics of the virus. Although many studies have blamed severe 
activation of the immune system and excessive production of pro- 
inflammatory cytokines __known as cytokine storm__ to be the main 
cause of serious complications, this is lymphopenia and lymphocyte 
dysfunction that, at least partly, enforce disease progression in such 
way. The attention to the importance of lymphocytes in the pathogenesis 
of COVID-19 has been also increased by the recent disclosure that the 
virus-induced cytokine storm may be a compensatory mechanism 
adopted by the host immune system to cover the lack of lymphocytes 
and their exhausted phenotype. Since lymphocytes are the main immune 
cells battling with the beast of rapidly-evolving viruses, especially SARS- 
CoV-2, it comes as no surprise to assume that any abnormality in the 
frequency, specificity, function, and durability of these cells may 
contribute to the progression of COVID-19 toward an unfavorable 
outcome. All in all and taking advantage of these facts, it seems that the 
more accurate knowledge we gain about the role of lymphocytes in the 
pathogenesis of the disease, there would be the more ray of hope for the 
management and the treatment of the disease in the near future. In the 
present review, we discussed the role of each subtype of lymphocytes, 
including B cells, T cells, and NK cells, in the pathogenesis of COVID-19. 
We also provided brief information about the association between the 
lymphocytes and the disease prognosis, pathophysiology for lympho-
penia, and finally the lymphocyte- or lymphopenia-related treatment 
strategies in COVID-19 patients, especially those with severe disease. 
2. Lymphocytes in COVID-19 
From the first identification of COVID-19, one of the clinical mani-
festations that was highlighted in patients was the remarkable reduction 
in the number of peripheral lymphocytes. It was even more highlighted 
in severe cases, as the percentage of lymphocytes in this group dropped 
to lower than 20% [1]. The results of the flow cytometric analysis 
showed that SARS-CoV-2 may significantly decrease the number of 
lymphocyte subsets, including CD4+ T cells, CD8+ T cells, NK cells, and 
B cells [2–5]. Notably, CD8+ T cells seem to undergo a more significant 
reduction as compared to other subsets, especially in COVID-19 patients 
with a severe condition [6]. In another study, Qin et al. also indicated 
that reduction in the number of lymphocytes is not restricted only to the 
effector lymphocytes, as the number of memory T cells 
(CD3+CD4+CD45RO+) showed a remarkable reduction in severe dis-
ease, an event which suggested that why COVID-19 patients could not, 
at least in some cases, develop immunity against future infection with 
the virus [4]. The following parts of this paper try to gather evidence 
that takes a broad overview of the effects of COVD-19 on different 
subtypes of lymphocytes. 
2.1. B lymphocytes in COVID-19 
The impact of SARS-CoV-2 infection on plasmablasts (PBs) and 
memory B cells was first reported in a study conducted by Mathew et al. 
It became evident that while SARS-CoV-2 has no adverse effect on naïve 
B cells, it could significantly reduce the population of both class- 
switched (IgD− CD27+) and non–class-switched (IgD+CD27+) memory 
B cells. Conversely, the number of CD27− IgD− B cells, CD27+CD38+
PBs, and also KI67 expression in B cells was increased in the patients’ 
groups as compared to the control group [7]. The same results also 
announced by Wen et al. who succeeded to identify four B cell sub- 
populations in COVID-19 patients using scRNA-seq: naïve B cells that 
express CD19, CD20 (MS4A1), IGHD, IGHM, IL4R, and TCL1A; memory 
B cells, which are detected by the expression of CD27, CD38, and IGHG; 
immature B cells (B3) that express CD19 and CD20; and plasma cells 
(B4) expressing high levels of XBP1 and MZB1. Their results suggested 
that while the percentage of naïve B cells was reduced during COVID-19, 
the number of plasma cells was increased in patients. Additionally, 
unlike the B cells isolated from healthy donors, those B cells harvested 
from recovered patients displayed an elevation in the expression of 
S100A8, IGLL5, SSR3, IGHA1, XBP1, and MZB1, which are known as 
activation-related genes [8]. Vassallo et al. also reported that there is an 
association between higher CD10+ B lymphocyte levels and the devel-
opment of a mild type of COVID-19 disease [9]. 
Humoral responses in COVID-19 are often of limited durability, as 
seen with other human coronavirus epidemics. In an interesting study, 
Pillai et al. showed that while the germinal centers in either lymph nodes 
or spleen are destroyed and the number of Bcl-6+ B cells diminished 
significantly, the number of AID+ B cells remained unchanged. These 
data provide valuable supports for why antibody responses are restricted 
in COVID-19 infection. In fact, dysfunction of Bcl-6+ T follicular helper 
(TFH) cells and disturbed humoral immune responses at the early stage 
of the disease may be responsible for the rapid distribution of the virus 
into vital organs. In a plain word, the differentiation arrest of Bcl-6+ TFH 
cells in the germinal center may result in loss of this zone in lymphoid 
organs and accumulation of non-germinal center-derived activated B 
cells [10]. 
2.1.1. The role of antibodies in COVID-19 
The humoral immune responses against enveloped viruses include 
the production of a wide range of immunoglobulins (Ig), foremost IgM, 
IgG3, IgG1, and IgA, which are mainly specific to the glycoproteins and 
the nucleoproteins of the envelope. Although the presence of antibodies 
to the nucleoproteins is representative of the infection, there are no 
enough studies suggesting how they precisely hamper the replication of 
the virus [11,12]. Fourteen days after the onset of symptoms, IgM and 
IgG against spike protein (SP) of the SARS-CoV-2 envelope are detect-
able in the majority of COVID-19 patients. The results of the in vitro 
analysis suggested that these antibodies, which mostly recognize the 
receptor-binding domain (RBD) of the SP, could neutralize the replica-
tive capacity of the virus and act as neutralizing antibodies [13–15]. 
In a study conducted on a total of 222 patients, the authors found 
enhanced IgM levels at the early stage with this notion that its level was 
higher in patients with the severe form of the disease. Also, high levels of 
IgG were detected in severe cases of COVID-19 but it was increased at 
the late stage [16]. Since IgG levels were higher in the critically ill pa-
tients, the high titer of this antibody is mostly considered to be a worse 
prognostic factor [16]. However, it should be noted that antibody re-
sponses are different in each individual and the early peak level of an-
tibodies could not be an indicator of a better outcome, as some severe 
cases had a high concentration of Abs at the early stages of the disease 
[14]. Inline, Lee et al. examined SARS-CoV-1 IgG concentrations and 
suggested that patients who seroconverted earlier in the course of the 
disease progressed to a more aggressive type of the disease [17]. Zhang 
et al. also suggested that patients with a high level of IgG were more 
prone to develop a more severe type of disease as compared to those 
with a lower level [16]. They indicated that probably antibody- 
dependent enhancement (ADE) __that is a mechanism in which binding 
of a virus to sub-neutralizing or cross-reactive non-neutralizing antiviral 
antibodies reinforces its entry, and subsequently, enhances virus repli-
cation__ may be responsible for this phenomenon [18,19]. Aside from 
protective functions, it seems that the produced IgG against SARS-CoV-2 
SP can boost the infection of immune cells and undesirably enhance the 
immunopathogenesis of COVID-19. To provide a better overview, we 
designed a schematic figure representing the roles of B cells in COVID-19 
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in Fig. 1. 
2.2. T Lymphocytes in COVID-19 
Studies show SARS-CoV-2-specific CD4+ and CD8+ T cells __in har-
mony with other components of the immune system__ first fight acute 
viral infection and then protect the body against re-infection. The results 
of some studies show that the number of T cells in severe and critically ill 
patients is significantly less than those who have mild/moderate cases of 
COVID-19. Among the different types of immune cells, it seems that T 
cells are more vulnerable to SARS-CoV-2, as the number of these cells is 
reduced to half the reference limit. Moreover, there is a correlation 
between the age and the number of T cells in COVID-19, as the patients 
with the age older than 60 tend to have a lower number of T lympho-
cytes; an event which may explain, at least partially, why older patients 
are at a higher risk for the SARS-CoV-2 infection [20,21]. Apart from an 
alteration in T cell count, there are several studies that have investigated 
the effect of SARS-CoV-2 on T cell activation. A study provides evidence 
of T cell activation in mild disease, but not severe, as compared to 
healthy controls [20]. While the superiority of CD8+ T cell activation to 
CD4+ T cells was evident in some reports [20,22], another study 
demonstrated that CD4+ T cell activation was more pronounced in pa-
tients with the clinically more severe condition [7]. In the following, we 
discuss separately the CD4+ and CD8+ T cell responses to SARS-CoV-2 
infection. 
2.2.1. CD4+ T cell responses in COVID-19 
Grifoni et al. showed that the stronger SARS-CoV-2-specific CD4+ T 
cell responses would result in a greater level of antibody in COVID-19 
patients. The results of TCR-dependent AIM assays revealed that 
SARS-CoV-2 spike-specific CD4+ T cells are detectable in all the cases 
with COVID-19. Their results also showed that COVID-19 infection 
Fig. 1. A glance at the effect of SARS-CoV-2 
on B lymphocytes. While infection with 
SARS-CoV-2 decreases the number of both 
naïve and memory B cells (switched and non- 
switched) (a), the percentage of plasma-
blasts, plasma cells, and IgD-/CD27- B cells is 
increased noticeably in COVID-19 patients 
(b). Moreover, B cell activation-related 
genes, such as S100A8, IGLL5, SSR3, 
IGHA1, XBP1, and MZB1 were mainly 
expressed in the memory B cells and plasma 
cells (MPBs) (c). There is also evidence of 
prominent loss of germinal centers in the 
lymph nodes and spleen coupled with the 
depletion of Bcl-6+ B cells but the mainte-
nance of AID+ counterparts in acute COVID- 
19, which in turn, lead to reduced durability 
of humoral responses (d). Due to the eleva-
tion in the amount of sub-neutralizing or 
cross-reactive non-neutralizing antiviral an-
tibodies especially IgG, a mechanism entitled 
antibody-dependent enhancement (ADE) 
happens by which the pathogenesis of 
COVID-19 is boosted via enhanced viral 
replication (e).   
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mostly stimulated TH1 cell polarization, since they produced a signifi-
cant amount of IFNγ rather than IL4, IL5, IL13, or IL17a [23]. In 
agreement, Chen et al. declared that the proportion of IFNγ-producing 
TH1-like cells was higher in moderate COVID-19 cases compared to 
those with a severe condition [24]. While the role of TH2 responses in 
SARS-CoV-2 infection is not fully described, there are several studies 
proposing a potential role for TH17. In a study conducted by Xu et al, it 
has been indicated that the concentration of highly pro-inflammatory 
CCR6+ TH17 cells was increased significantly [25]. The frequency of 
different types of CD4+ T cells, including naïve T cells, effector memory 
T cells (EM-1/2/3), central memory T cells (CM), and CD45RA+ effector 
memory cells as well as circulating TFH (cTFH) cells were examined in 
COVID-19 cases in an interesting study conducted by Mathew et al. 
While the population of naïve CD4+ T cells was diminished in COVID-19 
cases, the populations of both EM2 and CD45RA+ effector memory cells 
were increased significantly. Also, the number of activated cTFH cells 
[CD38+ ICOS+] was higher in recovered donors than in healthy donors, 
perhaps reflecting residual COVID-19 responses in the former [7]. 
Accordingly, it has been indicated that the number of memory CD4+ T 
cells with high levels of IL-7Rα (CD127) was significantly increased in 
the recovered donors. Indeed, patients with SARS-CoV-2-specific mem-
ory T cells have a higher chance of disease recovery, and the risk of 
COVID-19 is extremely low in individuals with peripheral COVID-19- 
specific memory T cells [26]. Taken together, CD4+ T cells are 
directly and indirectly involved in the immune response against COVID- 
19 infection not only by the coordination of anti-viral responses but also 
via hampering the ability of SARS-CoV-2 to replicate; however, there are 
several studies now underway to precisely elucidate whether CD4+ T 
cells are over-activated or functionally impaired within acute phase of 
COVID-19. 
2.2.2. CD8+ T cell responses in COVID-19 
It was at the early stages of the COVID-19 outbreak that the adverse 
impact of the virus on the number, activation, as well as differentiation 
status of CD8+ T cells, known as cytotoxic T cells (CTL), became evident 
in the severe cases. By using an activation-induced marker (AIM) and 
intracellular cytokine staining (ICS) assays, Grifoni et al. provide evi-
dence suggestive of the prominent participation of CD8+ T cells against 
SARS-CoV-2 in the recovered COVID-19 patients [23]. Accordingly, it 
has been declared that CD8+ T cell clonal expansion either in bron-
choalveolar lavage fluid [27] or peripheral blood [28] was directly 
correlated with COVID-19 recovery or the emergence of milder condi-
tion; however, the question concerning the fact that it is the reason or 
result of the recovery is still open to debate. In an interesting study and 
based on the increased ratio of CD4+ T cells to CD8+ T cells in COVID-19 
patients, the authors concluded that probably cytotoxic T cells were 
migrated to the respiratory tract [29]. Accordingly, the results of a study 
conducted by Jiang et al. shed light on the fact that there is a negative 
correlation between the number of CD8+ T cells and their activity during 
COVID-19 progression. In fact, they claimed that as the virus could 
probably diminish the population of peripheral lymphocyte subsets, the 
activity of CD8+ T cells is compensatorily reinforced to bypass the 
pathogenesis of the virus [20]. In this vein, a previous study suggested 
the presence of an overaggressive CD8+ T cell response in COVID-19 
cases [30]. Also, increased cytotoxicity of CTLs has been proposed in 
several studies as CD8+ T cells could express high levels of NK cell- 
related markers [31–33]. 
It has been indicated that the number of Ki67+ proliferating CTLs or 
activated CD8+ T cells that express CD38 and HLA-DR may be remark-
ably increased after vaccination with live-attenuated viruses or during 
the acute phase of a viral infection; an event which may possibly reflect 
the contributory role of virus-specific CTLs [34]. Accordingly, several 
studies are suggesting that the percentage of the aforementioned cells 
may elevate in most, if not all, of COVID-19 patients [31,35–37]. In 
addition, recent disclosures provide evidence indicating an increased 
number of SARS-CoV-2-specific CTLs in recovered COVID-19 cases 
[38–40]; further highlighting the fact that virus-specific CD8+ T cell 
responses may be in charge of battle with the SARS-CoV-2 virus. 
Although there is implicit agreement on the role of CD8+ T cells in the 
response against SARS-CoV-2, there are still conflicting issues that must 
be considered. In fact, one of the most important of these is how the 
results achieved through examination of T cell responses in peripheral 
blood can be generalized to lung events. Also, different CTL responses 
according to disease features should be considered while investigating 
adaptive immunity and its ability to defend from future infection with 
SARS-CoV-2. 
2.2.3. Regulatory T cells in COVID-19 
As regulatory T cells (Tregs) have a fundamental role in the main-
tenance of immune homeostasis, the reduction in the number of this 
group of lymphocytes during COVID-19 infection may be coupled with 
the aberrant activation of the immune system and subsequently induc-
tion of tissue damage, especially in the lungs, where the infection has the 
most activity. A remarkable decrease in the population of Tregs has been 
reported in COVID-19 patients, especially in the severe group 
[20,41,42]. Although there is little evidence about the mechanism that 
is responsible for the reduction of circulating Tregs, one of the most 
possible scenarios is they migrate to the lungs in order to protect the host 
cells from the deteriorating effects of immune responses. Notably, there 
is a piece of evidence showing that the Middle East coronavirus pos-
sesses the ability to infect T cells [43]; so there is a possibility that the 
reduction of Tregs in COVID-19 patients may be attributed to the direct 
impact of the virus on these cells [44]. Decreased transcription of IL-2 
has been also detected in the isolated CD4+ T cells from the bron-
choalveolar lavage of severe COVID-19 patients. One of the obvious 
conclusions that can be drawn is that the reduction in IL-2 is associated 
with Tregs apoptosis, which was further confirmed by the reduced 
expression of FoxP3 [44]. Additionally, the identification of elevated 
concentrations of soluble CD25 (sCD25) in severe cases of COVID-19 
patients [2] shed light on the possibility that COVID-19-induced 
inflammation may cleave cell surface CD25 and release it in the form 
of sCD25 in the bloodstream. Soluble CD25 now has the ability to 
interact with IL-2 and prevent its association with CD25 expressed on 
Tregs, thereby trigger apoptosis. 
2.2.4. T Cell exhaustion 
The decrease in the number of T cells is not the only abnormality 
during COVID-19 infection, as due to the severe and prolonged infection 
a group of T cells may acquire the exhausted phenotype that is mainly 
detectable by the massive expression of markers known as exhausted 
markers, including PD-1 (programmed cell death 1; CD279) and TIM-3 
(T cell immunoglobulin and mucin domain-containing-3; CD3 
[21,45,46]. In fact, the increase in the expression of PD-1 and Tim-3 is 
representative of the progression of the disease from prodromal to 
symptomatic stages. FACS analysis in severe cases of COVID-19 patients, 
especially those who were admitted to ICU, revealed a higher expression 
of PD-1 as compared to healthy counterparts, suggestive of the ability of 
SARS-CoV-2 in enforcing T cells to express exhaustion markers [21]. 
Weiskopf et al. suggested Tim-3 overexpression as a hallmark of poor 
prognosis in COVID-19 patients [30]. Apart from the indicated markers, 
elevation in the expression levels of NK group 2 member A (NKG2A) on 
either NK cells or effector T cells was reported in COVID-19 patients. 
Indeed, expressed NKG2A could halt the cytotoxic effects of these anti- 
viral members of the immune systems and lead to disease progression 
[47]. Interestingly, Zheng et al. found that decreased expression of 
NKG2A was coupled with the elevation in the number of cytotoxic 
lymphocytes (NK cell and T cells) after disease recovery [24]; shedding 
more light on the competency of exhausting markers as plausible 
prognostic factors. 
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2.3. NK cell responses in COVID-19 
Natural killer (NK) cells are one of the most important arms of the 
innate immune system that their significant responsibility is to defend 
against viral infections at the initiating stage without the need for spe-
cific identification of antigens. Also, by constructing a network with 
other immune cells like dendritic cells, NK cells are enabled to simul-
taneously transmit the stimulating signal to the adaptive arm of the 
immune system [48]. It seems that NK cells are one of the targets of 
SARS-CoV-2, as several pieces of evidence clearly showed their reduc-
tion in COVID-19 patients, especially those who are classified as criti-
cally ill [8,45,49]. Despite a piece of evidence, still it is ambiguous 
whether the reduction in the number of NK cells is due to the ability of 
the virus to induce apoptotic death or is due to their redistribution into 
infected sites. In support of the latter, the identification of a great 
number of NK cells in bronchoalveolar lavage fluid (BALF) samples from 
COVID-19 patients clearly suggests that NK cells are accumulated in the 
lungs during viral infection [50]. In another analysis of BALF samples of 
COVID-19 patients, while the number of quiescent NK cells was reduced, 
there were no differences in the population of activated NK cells [45]. 
Apart from the decreased number, there are also several studies 
reporting SARS-CoV-2-induced effects on the function of NK cells. 
Notably, while the expression of Granzyme A (GrA) was increased in NK 
cells in mild and severe types of the disease, their capability to express 
this enzyme was reduced as the disease progressed into more serious 
stages [20]. As mention previously, Zheng et al. hypothesized that due to 
the induction of exhaustion phenotype in NK cells during COVID-19 
infection, the innate immune responses might be severely compro-
mised in severe cases of the disease [45]. It has been indicated that local 
and systemic inflammation, specifically increased secretion of IL6 by the 
infected dendritic cells and macrophages, could suppress GrB expression 
and hamper NK cell cytotoxicity in COVID-19 [51]. IL-6 could also halt 
the expression of NKG2D, one of the leading receptors on the surface of 
NK cells that are responsible for eliminating infected cells [52]. All in all, 
the abstract of these finding suggests that while a group of NK cells 
abandon peripheral blood and migrate to the lungs to defend against the 
virus, an event which ultimately results in local inflammation and 
injury, circulating NK cells undergo the exhaustion phenotype that 
Fig. 2. A glance at the effect of SARS-CoV-2 on T cells and NK cells. Both CD4+ and CD8+ T cells __specific against different parts of the virus including spike (S), 
membrane (M), nucleocapsid (N), and nonstructural proteins (NSPs)__ were recognized in 100% and 70% of convalescing COVID-19 patients’ epitope pools, 
respectively. Spike-specific CD4+ T cell responses were associated with the elevation in the amount of the anti-virus IgG and IgA (a). In addition, SARS-CoV-2 
infection frequently stimulated TH1 cell polarization, as they produced a high level of IFNγ. Also, the percentage of TH17 may increase in COVID-19 patients 
(b). The virus endocytosis and degradation are taken place by the APCs like dendritic cells (DCs) and then the antigens of the virus are presented by MHCs to the T 
cells. When a CD8+ T cell binds to MHC-I, clonal expansion occurs and infected cells are directly targeted via secretion of cytotoxic proteins, such as perforin and 
granzymes. In the case of CD4+ T cells involvement, they can activate SARS-CoV-2-specific B cells to clonally proliferate and secrete antibodies to target the SARS- 
CoV-2 virus (c). The CD4:CD8 ratio is increased in COVID-19 patients which may be explained, at least partly, by the migration of CD8+ T cells to the respiratory 
tract. Also, the percentage of circulating Tregs is decreased mainly due to apoptosis of these regulatory cells as a result of IL-2 neutralization by the increased level of 
sCD25 (d). Increased secretion of pro-inflammatory cytokines leads to over-expression of PD-1, Tim-3, and NKG2A, which is suggestive of the ability of SARS-CoV-2 
in enforcing exhaustion phenotype in T cells (e). Also, IL6 could hamper the expression of both GrB and NKG2D, an event which in turn leads to decreased cyto-
toxicity of NK cells (f). 
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paralyzes the immune system to prevent virus spread. Fig. 2 represents a 
schematic to provide a well-conceptualized overview of the roles of T 
cells and NK cells in SARS-CoV-2 infection. 
Taken all together, infection with SARS-CoV-2 may affect B cells, T 
cells, and NK cells. Concerning B lymphocytes, SARS-CoV-2 decreases 
the number of both naïve and memory B cells. There is also evidence of 
prominent loss of germinal centers in the lymph nodes and spleen 
coupled with the depletion of Bcl-6+ B cells in acute COVID-19 which 
may explain, at least partly, the low durability of humoral responses. In 
the case of CD4+ T cell involvement, SARS-CoV-2 infection frequently 
stimulates polarization of TH1 cells which are able to activate specific B 
cells to clonally proliferate and secrete antibodies to target the virus. On 
the other hand, virus-specific CD8+ T cells can directly target infected 
cells via secretion of cytotoxic proteins, such as perforin and granzymes. 
While SARS-CoV-2 can reduce both CD4+ and CD8+ T cells, it mainly 
affects the latter as the ratio of CD8:CD4 often decreases in COVID-19 
patients. Also, this infection may reduce the percentage of circulating 
Tregs mainly due to apoptosis induction as a result of IL-2 neutralization 
by the increased level of sCD25. Induction of exhausted T cells and NK 
cells also should be taken into account as an important way that SARS- 
CoV-2 may apply to hamper host immunity. 
3. Prognostic factors associated with lymphocytes in COVID-19 
3.1. Lymphocyte count 
Several pieces of evidence suggest that lymphocyte count can be a 
valuable parameter for risk stratifying of COVID-19 patients into 3 
groups of moderate, severe, and critically ill. This idea is originated from 
the fact that the total number of lymphocytes may be significantly 
diminished in COVID-19 patients, with the notion that the reduction is 
more highlighted in the critically ill patients [20]. A significant decrease 
of T lymphocytes has been also shown to be positively correlated with 
in-hospital death and severity of illness [53]. Accordingly, Huang et al. 
demonstrated that patients with increased mortality, acute respiratory 
distress syndrome, and those who need intensive care have a lower 
number of lymphocytes as compared to their counterparts with better 
prognosis [54]. The results of a recent meta-analysis suggested that the 
estimated pooled mean of lymphocytes in non-severe cases was 0.95 
(95% CI, 0.81–1.10), whereas it was 0.70 (95% CI, 0.52–0.87) in severe 
COVID-19 patients (P < 0.01) [55]. The same result was obtained in 
another study conducted by Bermejo-Martin et al. [56] who introduced 
lymphopenia as a severe COVID-19 signature. Notably, lymphopenia 
was common in the critically ill patients with the MERS infection which 
may be a result of lymphocytes apoptosis [57,58]. Overall, these find-
ings indicated that the number of lymphocytes retains a specific clinical 
and biological significance in COVID-19 and lymphopenia is seemingly 
an important hematological abnormality that contributes to mirror the 
evolution toward an unfavorable outcome. 
3.2. TLM (time to lymphocyte model) 
Tan et al. have established a new index for categorizing COVID-19 
patients according to a time to lymphocyte model (TLM). Based on 
their observation, the lymphocyte count of the patients could be used to 
determine the prognosis of the patients; however, the results might be a 
bit different according to the time of evaluation. At the first time period 
(TLM-1), which is in 10–12 days after the onset of the symptoms, those 
whose lymphocyte percentage (LYM%) is higher than 20 would have a 
moderate form of the disease and conversely, those with LYM% lower 
than 20 are categorized as high risks. If LYM% is evaluated 17 to 19 days 
after the manifestation of the symptoms, known as TLM-2, the classifi-
cation of the patients is quite different. LYM% higher than 20 is sug-
gestive of the recovery of the patients, LYM% between 5 and 20 is 
showing that the patient still needs supervision, and less than 5 is 
indicative of the patient with a high risk of mortality who needs 
intensive care [59]. 
3.3. NLR (neutrophil to lymphocyte ratio) 
The ratio of neutrophil to lymphocyte counts, known as NLR, is a 
predominant biomarker of systematic inflammation and is widely used 
in bacterial infections to predict the outcome of the patients, especially 
those who have pneumonia. Bacterial infections are not the only con-
dition in which calculating NLR would be beneficial, as this index could 
provide valuable information about the prognosis of patients in different 
types of diseases ranging from human cancers to other inflammatory 
diseases such as acute coronary syndrome, intracerebral hemorrhage, 
polymyositis, and dermatomyositis. Interestingly, it became recently 
evident that the shift in the count of WBCs towards neutrophils rather 
than lymphocytes occur in severe cases of COVID-19, suggesting that 
probably the calculation of NLR could help the physician to appropri-
ately risk stratify the patients [20]. Feng et al. designed an interesting 
study to investigate if there is a correlation between NLR and prognosis 
in COVID-19 patients. In their study, they observed a significant increase 
in NLR during the severe phase [60]. Their results have been confirmed 
by a study conducted by Eid et al. They indicated high sensitivity of this 
ratio in patients aged over 50 years and suggested it as a quick and 
simple tool with excellent efficacy for screening patients who need more 
attention and careful evaluation due to their high vulnerability to the 
respiratory deterioration [61]. A double-center study also obtained 
interesting results as they found that patients with NLR value greater 
than 6.5 had more complicated clinical outcomes and those with NLR 
value of 9 or higher mostly faced death [62]. 
3.4. PLR (platelet to lymphocyte ratio) 
The platelet to lymphocyte ratio (PLR) is confirmed to be a good 
candidate for predicting the outcome of patients with different diseases, 
including human cancers, acute pancreatitis, and cardiovascular dis-
ease. Meng et al. reported the correlation between PLR and disease 
severity in hepatitis C-infected patients [63]. The same result was re-
ported by Ye et al. who showed that acute heart failure (AHF) patients 
with the higher PLR experienced a poorer outcome [64]. Notably, it has 
been indicated that PLR could be an indicator of disease severity in 
COVID-19 cases and may be helpful in predicting disease prognosis [65]. 
According to a recent investigation perform by Qu et al., while univar-
iate analysis introduced both age and PLR as prognostic factors for 
COVID-19 patients, the multivariate analysis failed to find an associa-
tion between these parameters and the outcome of the patients. They 
also reported that ΔPLR could provide a valuable schematic about the 
duration of hospitalization of patients; the higher the value is, the longer 
patients should stay at the hospital [66]. Lu et al. revealed that once 
patients improve (on the 14th day), the value of RLP is going to decrease 
and gradually be close to normal [67]. Taken together, all these results 
shed light on the fact that PLR may probably serve as one of the key 
prognostic factors in the COVID-19 infection. 
3.5. Existence of atypical lymphocytes 
The role of atypical lymphocytes (ALC), which are a group of me-
dium to large size lymphocytes with the condensed chromatin and 
basophilic cytoplasm, in the prognosis of infectious diseases is still a 
debatable issue. For example, while Clarice et al. indicated that ALC is a 
marker of poor prognosis in patients with severe dengue infection (DI) 
[68], other studies failed to find such a correlation [69]. In a study by 
Jamal et al., it has been established that the presence of ALC in the 
peripheral blood of COVID-19 patients is a common event, even in cases 
with lymphopenia. More interestingly, unlike other viral infections in 
which the presence of classic Downey II-like cells are very common, 
SARS-CoV-2 infection is associated with the presence of atypical plas-
macytoid lymphocytes in the peripheral blood [70]. Accordingly, Foldes 
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Table 1 
A summary of the prognostic factors associated with lymphocytes in COVID-19.   
Patients 
No. 
Age (Y) Female Outcome Ref 
Lymphocyte count  
198 X: 50 49% In this single centre cohort of 
COVID-19 patients, the most 
common symptom was fever, and 
the most common laboratory 
abnormality was decreased blood T 
cell counts (45.8% patients on 
admission). Patients admitted to 
ICU were older and had a 
significant reduced T lymphocytes. 
[72]  
452 M: 58 48% T lymphopenia, in particular, 
decrease of CD4+ T cells, were 
common among patients with 
COVID-19, and more evident in the 
severe cases. But no significant 
change was observed in the 
number of CD8+ cells and B cells. 
[20]  
187 M: 62 45% As the severity of COVID-19 
getting worse, the counts of T 
lymphocyte drop lower. 28 
patients died in hospital, the 
median T and B lymphocyte were 
significantly lower in the expired 
cases than other patients. Lower 
counts (/µL) of T lymphocyte 
subsets and B cells were associated 
with higher risks of in-hospital 
death of CIVID-19. 
[73]  
1099 M: 47 42% Lymphopenia was present in 
83.2% of the patients on 
admission, and patients with 
severe disease had more prominent 
lymphopenia and leukopenia than 
those with non-severe disease. 
[74]  
191 ≥18 38% Baseline lymphocyte count was 
significantly higher in survivors 
than non-survivors. In survivors, 
lymphocyte count was lowest on 
day 7 after illness onset and 
improved during hospitalization, 
whereas severe lymphopenia was 
observed until death in non- 
survivors 
[75]  
135 M: 47 50 Compared to the mild cases, the 
severe ones had lower lymphocyte 
counts and higher plasma levels of 
d-dimer, LDH, and CRP 
[76]  
138 M: 56 46% During hospitalization, most 
patients had marked lymphopenia, 
and non-survivors developed more 
severe lymphopenia over time. 
White blood cell counts and 
neutrophil counts were higher in 
non-survivors than those in 
survivors. 
[77]  
242 M: 57 50% Lower lymphocyte percentage was 
found in severe cases, compared to 
non-severe cases. Noticeably, the 
percentages, but not absolute 
counts of lymphocytes, were lower 
in severe patients when compared 
to non-severe patients. 
[78]  
150 <20–90 NA There were significant differences 
in white blood cell counts, absolute 
values of lymphocytes, CRP, and 
IL-6 between died and discharged 
groups. 
[79]  
52 M: 60 43% Lymphopenia occurred in more 
than 80% of critically ill patients. 
In non-critical, 35% of patients had 
only mild lymphopenia, suggesting 
that the severity of lymphopenia 
[75]  
Table 1 (continued )  
Patients 
No. 
Age (Y) Female Outcome Ref 
reflects the severity of SARS-CoV-2 
infection.  
112 NA NA Compared with the general group, 
the lymphocyte count (0.74 × 109/ 
L vs. 0.99 × 109/L, P = 0.03) was 




452 M: 58 48% A higher number of neutrophils 
and a lower number of 
lymphocytes were found in the 
severe group with COVID-19 
compared to the mild group. 
[20]  
245 X: 54 53% There was 8% higher risk of in- 
hospital mortality and the fully 
adjusted OR for mortality was 1.1 
in males for each unit increase in 
NLR. NLR is an independent risk 
factor of the in-hospital mortality 
for COVID-19 patients especially 
for male. 
[81]  
1320 M: 52 39% NLR greater than 6.5 may reflect 
the progression of the disease 
towards an unfavorable clinical 
outcome, with this notion that the 
ratios higher than 9 may strongly 
result in death. 
[62]  
93 M: 46 50% Elevated age and NLR can be 
considered independent 
biomarkers for indicating poor 
clinical outcomes. 
[65]  
301 M: 51 50 Having an NLR ⩾2.973 (HR 2.641, 
95% CI 1.421–4.908; p = 0.002), 
age ⩾50 years (HR 2.504, 95% CI 
1.202–5.215; p = 0.014) and being 
male (HR 2.004, 95% CI 
1.101–3.647; p = 0.023) were 
identified as risk factors for 
progression by multivariate Cox 
regression analyses. 
[82]  
74 M: 63 31% Patients with severe disease were 
significantly older and had a 
significantly higher NLR compared 
with non-severe cases. A higher 
NLR at hospital admission was 
associated with a more severe 
outcome: in particular, a NLR of 
greater than 4 was a predictor of 
admission to the ICU. 
[83]  
131 M: 64 57% The NLR of 3.3 was associated with 
all-cause mortality, with a 
sensitivity of 100% and a 
specificity of 84%. NLR of 2.3 
might have potential value for 
helping clinicians to identify 
patients with severe COVID-19, 
with a sensitivity of 100% and a 
specificity of 56.7%. 
[2]  
225 M: 60 42% Not only admission NLR correlated 
with mortality but also the nadir 
quantity of NLR was higher in the 
non-survived patients. NLR was 
higher than 3 in all of the deceased 
patients, and it seems that elevated 
NLR could be used as a prognostic 
value for improved mortality 
prediction. 
[84]  
81 X: 50 37% NLR could be a valuable biomarker 
to recognize severe COVID-19 
patients with moderate-severe 
ARDS, which facilitated clinicians 
to give effective respiratory 
supporting strategies and quickly 
find out moderate-severe ARDS 
[85] 
(continued on next page) 
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et al. reported that blood film of COVID-19 showed Mott cells, which are 
a group of ALCs with noticeable cytoplasmic inclusions [71]. Taken 
together, the presence of atypical lymphocytes has been shown in 
COVID-19 patients, but the association between these lymphocytes and 
the severity of the disease is still unclear and further studies are needed. 
To provide a well-conceptualized overview of the prognostic factors 
associated with lymphocytes in COVID-19, we summarized all these 
data in Table 1. 
4. Pathophysiology for lymphopenia in COVID-19 
4.1. Direct infection of lymphatic organs 
One of the main mechanisms that causes lymphopenia in COVID-19 
patients could be due to the direct attack of SARS-CoV-2 on lymphatic 
organs, such as the thymus and spleen [87]. Ding et al. have previously 
reported that the SARS virus could destroy the germinal centers, espe-
cially in the pulmonary hilar lymph nodes [88,89]. A mounting body of 
evidence showed that SARS infection is associated with the atrophy of 
splenic white pulp and disappearance of the germinal centers [89–92]. 
The same results were obtained by Falasca et al., who reported that the 
splenic white pulps of COVID-19 patients showed lymphoid hypoplasia 
with congested red pulp [93]. Notably, direct destruction of some 
lymphatic organs such as lymph nodes and spleen with COVID-19 has 
been reported by Feng et al. Their histopathological examination 
showed that the spleens were congested, hemorrhagic, and the spleen 
corpuscles were atrophic with increased fibrous tissue hyperplasia in the 
splenic sinus [94]. They also proposed a model in which SARS-CoV-2 
disseminates to the secondary lymphoid organs, leading to Fas up- 
regulation and IL-6 secretion, which in turn, trigger activation- 
induced cell death in lymphocytes resulting in lymphopenia. Interest-
ingly, the authors detected that ACE2-expressing CD68+CD169+ mac-
rophages were in the splenic marginal zone and marginal sinuses of 
lymph nodes. In addition, the expression of IL-6 was elevated in SARS- 
CoV-2 infected macrophages which have nucleoprotein antigen. Of 
particular interest, the results of the tunnel test indicated that apoptosis 
and disorganization in the secondary lymphoid organs of COVID-19 
patients were very common [94]. In another study, Liu et al. reported 
that the postmortem spleens were generally contracted with shrinking 
capsules, mixed thrombi, hemorrhage, and anemic infarction. Moreover, 
COVID-19 spleens showed a prominent absence of lymphoid follicles as 
compared to control spleens from patients with abdominal trauma 
necessitating splenectomy [95]; further highlighting the deteriorating 
effect of SARS-CoV-2 on the spleen. Elsoukkary et al. also indicated that 
the subcapsular and intraparenchymal sinuses of the spleen and/or 
lymph nodes were enlarged and often contained a variable number of 
larger transformed cells [96]. All in all, these results further highlighted 
the probable ability of COVID-19 to induce direct damage to lymphoid 
tissues and lymphopenia under its influence; however, this hypothesis 
requires to be validated by further comprehensive pathological studies. 
4.2. Direct infection of bone marrow 
The evidence supported that the influence of SARS-CoV-2 on 
lymphocyte precursors could also be traced back to bone marrow (BM), 
where hematopoietic stem cells (HSCs) developed into common 
lymphoid progenitors (CLP). This idea has been developed from the 
recent disclosure which indicated the high expression of both CXCL10 
and CCL2 in COVID-19 patients, especially in severe cases who suffer 
from lymphopenia [97–99]. The suppressive impacts of these chemo-
kines on the survival of HSCs have been well-established in previous 
reports and it could be assumed that perhaps the overexpression of 
CXCL10 and CCL2 might be involved in the SARS-CoV-2-mediated 
lymphopenia [100]. Microscopic analyses of BM in COVID-19 de-
cedents also showed several abnormalities, including increased 
myeloid/erythroid (M/E) ratio, a relative increase in overall cellularity, 
and in particular, the presence of scattered macrophages that engulfed 
erythroid cells which is consistent with the diagnosis of hemophagocytic 
histiocytosis [101]. The same result was obtained in a study conducted 
by Falasca et al., who reported the presence of numerous macrophages 
with the features of hemophagocytosis. Notably, the results of BM ex-
amination showed a prominent white pulp lymphoid hypoplasia 
coupled with conspicuous hyperplasia in the megakaryocyte lineage 
[93]. Another point that could confirm the destructive effects of SARS- 
CoV-2 on BM and its residential cells is the high expression of the 
Table 1 (continued )  
Patients 
No. 
Age (Y) Female Outcome Ref 
patients who are at high indication 
for V-V ECMO.  
100 X: 52 31% The NLR was found the most 
sensitive hematological marker 
with an AUC of 0.799 for ICU stay 
at 88% sensitivity and 90% PPV, 
while a value of 4.16 predicted 
mortality at a sensitivity of 91% 
and PPV of 96%. Around 90% of 
ICU patients along with non- 
survivors had NLR > 3 and one- 




30 M: 50 46% The PLR of patients might provide 
a new indicator in the monitoring 
of patients with COVID-19: the 
higher PLR of patients during 
treatment, the longer time of the 
hospitalization. 
[66]  
93 M: 46 40% The age and PLR of severe ill 
patients were significantly higher 
than those of non-severe patients. 
[65]  
131 M: 64 57% There were no significant 
differences in PLR for non- 
survivors, when compared to 
survivors. The PLR has no observed 
value for distinguishing the 
severity and predicting the death of 
patients with COVID-19. 
[2]  
225 M: 60 42% PLR correlated with mortality and 
was significantly higher in non- 
survivors. Elevated PLR and lower 
Hb at the time of admission 
associated with mortality and also 
ICU admission. 
[84]  
100 X: 52 31% PLR was elevated more in ICU (P =
0.004), and deceased patients. 
[86]  
Existence of atypical lymphocytes  
33 NA NA Atypical lymphocytic is common in 
SARS-CoV-2 patients’ peripheral 
blood. Specifically, atypical 
plasmacytoid lymphocytes are 
highly associated with SARS-CoV- 
2, which is unusual among viral 
infections. The classic Downey II- 
like cells, which are generally 
common in viral infections, are less 
frequently found in SARS-CoV-2 
infection. 
[70]  
1 59 0 Lymphoplasmacytoid lymphocytes 
with an eccentric nucleus, deeply 
basophilic cytoplasm and a 
prominent paranuclear hof were 
observed. 
[71] 
LDH: Lactate Dehydrogenase; CRP: C-reactive protein; NLR: Neutrophil-to- 
lymphocyte ratio; HR: Hazard ratio; V-V ECMO: Veno-venous extracorporeal 
membrane oxygenation; AUC: Area under the curve; PPV: Positive Predictive 
Value; PLR: Platelet-to-lymphocyte ratio; NA: Not available; X: Mean; M: Me-
dian; Y: Year. 
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ACE2 receptor in this organ. ACE2 receptor, as explained earlier, is the 
main receptor that participates in SARS-CoV-2 entrance into the target 
cells. Although the expression of this receptor seems to be low in BM, it is 
reasonable to assume that the devastating effect of SARS-CoV-2 on 
lymphocytes might, at least partly, be due to BM suppression [102]. 
However, further investigation in this field is required to validate this 
mechanism. 
4.3. Cytokine storm 
It has been suggested that the cytokine storm is probably the main 
player of COVID-19-induced lymphopenia. While the concertation of the 
pro-inflammatory cytokines is reduced to the normal level in recovered 
patients, basic researches confirmed the increased serum levels of pro- 
inflammatory cytokines and showed that up-regulated TNF-α and IL-6 
may take a part in the induction of lymphopenia through inducing 
apoptosis in T cells [103]. This disclosure was also confirmed by the 
results of autopsy studies on lymphoid tissues of COVID-19 patients, 
which showed massive lymphocyte death due to the high level of IL-6 
and Fas-FasL interactions [104,105]. Dia et al. also demonstrated the 
converse correlation between the number of lymphocytes and the serum 
levels of TNF-α, IL-6. Reciprocally, changes alteration in the level of the 
lymphocyte subgroups may also lead to an immune dysregulation with 
the induction of thumping cytokine and chemokine response, all of 
which may enhance cytokine storm leading to multi-organ dysfunction 
[21]. Although the lungs are the primary target sites affected by the 
elevated levels of these cytokines, the injury of non-pulmonary tissues is 
also common, and damage to the lymphoid organs such as the spleen 
and thymus shall not be considered an exception to this rule. Taken 
together, increased secretion of inflammatory cytokines may exacerbate 
lymphopenia, either through a direct or indirect manner, especially in 
severe cases of COVID-19. While previous studies reported that the 
excessive production of inflammatory cytokines may be in charge of 
COVID-19-induced lymphopenia, on the other hand, there may be a 
reciprocal connection suggesting that impaired lymphocyte activity may 
result in overproduction of pro-inflammatory cytokines in a compen-
satory manner. Indeed, it should be noted that the inability of the 
adaptive immune system in eradicating the viruses may result in the 
hyperactivation of the immune system, which in turn, causes the 
excessive release of inflammatory mediators to compensate either lym-
phopenia or lymphocyte dysfunction; an event that consequently may 
lead to the cytokine storm syndrome [106]. However, the precise 
mechanism of such an issue should be clarified. 
4.4. The emergence of metabolic disorders 
It has been shown that some metabolic products elevate the risk of 
poor disease outcomes and mortality in COVID-19, mainly through 
deregulation of the host immune system. In an interesting study, Fischer. 
et al. declared that exposure to external lactic acid resulted in the 
decreased proliferative capacity of human cytotoxic T lymphocytes via 
blockade of lactate efflux and thereby disturbance of T-cell metabolism 
[107]. Accordingly, Tan et al. reported the elevation in the lactic acid 
levels in severe COVID-19 patients and suggested it can diminish the 
proliferative capacity of lymphocytes [59]. The data extracted from a 
study conducted by Henry et al. indicated the correlation between 
elevated lactate dehydrogenase (LDH) and the development of the se-
vere form of the disease as well as the increased risk of mortality in 
COVID-19 cases [108]. Additionally, Lu et al. indicated that there is a 
significant difference between the levels of lactic acid and LDH in pa-
tients who suffer from severe COVID-19 and those who have a mild form 
of the disease [109]. In a similar study, the serum level of LDH has been 
proposed as a biomarker for risk stratification of the patients and also for 
monitoring the response rate to the treatment [110]. Cure et al. reported 
that Dapagliflozin __a sodium-glucose cotransporter-2 (SGLT2)__ is 
enabled to postpone the severe course of COVID-19 by preventing the 
acidification of cytoplasm and diminishing the proportion of viral par-
ticles [111]. The same result was obtained in a case report study con-
ducted by Chhetria et al. [112]. Lactic acid acidosis may also increase 
the risk of COVID-19 complications for patients through inhibition of 
lymphocyte proliferation, and subsequent lymphopenia [113]. 
4.5. Expression alteration of genes that are involved in lymphocyte 
proliferation/apoptosis 
SARS-CoV-2 can reduce the expression of certain genes that affect 
lymphocytes, thereby affecting the proliferation and activity of these 
cells. Xiong et al. indicated that several genes that are involved in the 
apoptosis pathways are upregulated in mononuclear cells of peripheral 
blood from COVID-19 patients; suggesting that lymphopenia may occur 
as a result of SARS-CoV-2-mediated apoptosis [114]. In this vein, the 
results of a previous study demonstrated that the infection of Vero E6 
cells (monkey kidney cells) with SARS-CoV induced death in the infected 
cells. As the phosphorylation level of p38 MAPK was increased 18 h post- 
infection in virus-infected cells, they suggested that the activation of this 
pathway may participate in SARS-CoV-induced cell death [115]. In 
addition, a report suggested that the expression levels of MAP2K7 and 
SOS1 were decreased in T cells of severe COVID-19 [105], which is in 
agreement with the results reported by Ouyang et al. Interestingly, while 
the expression of MAP2K7 and SOS1 were down-regulated during the 
disease progression, Ouyang et al. showed that the expression pattern of 
these genes was reversed and returned to normal levels upon recovery 
[116]; further highlighting the fact that the alteration of the afore-
mentioned genes may be considered, at least partly, as a mechanism 
underlying SARS-CoV-2-induced lymphopenia. 
4.6. Epigenetic alteration and dysfunction of lymphocytes 
One of the questions that occupied the mind of researchers from the 
emergence of COVID-19 infection was why some patients ended with the 
severe condition, while others may have mild respiratory disease. To 
answer this heterogeneity, many researchers have narrowed their view 
on epigenetic alteration as it is an age-related phenomenon 
[38,117–119]. The validation of this idea became even stronger when 
the evidence reported the presence of the methylation site on the CpG 
Island (cg08559914) located near the promotor of the ACE2 receptor, 
which controls the permeability of cells to SARS-CoV-2 [120]. Another 
support that suggested the importance of epigenetics in COVID-19 is the 
association between sex and the severity of the disease. It has been 
indicated that women with different age categories have a better 
outcome than men probably due to the sexual dimorphism in the im-
mune system. These results became even more interesting as previous 
studies suggested the higher frequency of lymphopenia in male patients 
compared to female counterparts [79,121]. Given these and based on 
the role of epigenetic alterations in regulation of lymphocyte functions 
in men and women [122,123], intense attention has been attracted to 
the role of this phenomenon in the vulnerability of lymphocytes to 
SARS-CoV-2. It did not take long that the correlation between age- 
associated DNA methylations and COVID-19-induced lymphopenia has 
been described. Wang et al. noticed that there is an association between 
the expressions of a histone methyltransferase G9a and lymphopenia 
incidence in COVID-19 patients. Their results suggested that those pa-
tients with overexpressed G9a had server conditions due to the 
impairment in T cell functions and excessive inflammatory responses 
[124]. Kouidou et al. also cited the correlation between ten-eleven 
translocase 2 (TET2) expression in COVID-19 patients and disease 
mortality due to the immune system failure, as TET2 is a DNA methyl-
transferase that widely regulates immune responses [125]. In another 
study, the results of genome-wide DNA methylation profiles revealed the 
presence of DNA methylation dysregulation in PBMCs harvested from 
COVID-19 patients. Their results showed the incidence of the hyper-
methylation pattern in the promotor of genes encoding different types of 
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INFs, as well as the hypo-methylation pattern of inflammatory-related 
genes [126]. Taken together, these findings not only shed light on one 
of the probable mechanisms through which SARS-CoV-2 may develop 
lymphopenia in patients but also suggested that perhaps the study of 
methylation pattern of some immunoregulatory genes in COVID-19 
could provide a new insight in stratifying the patients and predict 
their outcome [127]. 
4.7. Immune activation and increased expression of CD25 
When it comes to IL-2, many studies have tightened this cytokine to 
the proliferation, differentiation, and function of different types of T 
lymphocytes ranging from CD4+ T regs and helper T cells to CD8+
cytotoxic effectors [128]. Upon immune stimulation, CD25 (IL-2Ra) is 
expressed on activated T cells and its soluble form (sCD25) releases into 
the bloodstream to prevent the unnecessary activation of T cells. In 
many inflammatory-based diseases, extra-released sCD25 binds to IL-2 
and prevents its interaction with T lymphocytes, an event which in 
turn negatively regulates T cells, and may induce lymphopenia [44,54]. 
In a study done by Wang et al., they concluded that the level of sCD25 
was gradually increased with increased severity of illness but had no 
significant difference among the mild, severe, and extremely severe 
groups [41]. Hou et al. also found a negative association between sCD25 
and lymphocyte number. Interestingly, their finding was confirmed 
during disease recovery: while the concentrations of sCD25 were 
decreased, the number of lymphocytes was increased in recovered pa-
tients [129]. Taken together, these results shed light on the fact that 
increased levels of sCD25, especially in COVID-19 patients with severe 
illness, may cause lymphopenia by interfering with IL-2 signaling. Fig. 3 
was designed to provide a summary of the plausible mechanisms 
involved in COVID-19-induced lymphopenia. 
Fig. 3. Pathophysiology of lymphopenia in COVID-19. SARS-CoV-2 is also capable of inducing lymphopenia via direct destruction of lymphoid tissues, over-
expression of Fas, and stimulation of IL-6-producing macrophage (a). The overexpression of CXCL10 and CCL2, which have well-known suppressive impacts on the 
survival of HSCs, may cause reduced lymphopoiesis and might be involved in the SARS-CoV-2-mediated lymphopenia. The presence of scattered macrophages that 
engulfed erythroid cells is also a conspicuous finding in BM of COVID-19 patients (b). The increased serum levels of pro-inflammatory cytokines such as TNF-α and IL- 
6 may take part in induction of lymphopenia, either via a direct or indirect manner (c). Lactic acid acidosis may increase the risk of COVID-19 complications through 
blockade of lymphocyte proliferation and subsequent lymphopenia (d). Not only the transcription of apoptosis-related genes is increased in peripheral blood 
mononuclear cells (PBMNCs) but also the expression levels of proliferation-related genes (MAP2K7 and SOS1) are decreased, leading to reduced T cell proliferation 
(e). Extra-released sCD25 binds to IL-2 and impedes its interaction with T lymphocytes, an event that adversely affects T cell clonal expansion (f). 
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5. Treatment of COVID-19: Inhibiting inflammation-mediated 
lymphopenia and enhancing lymphocytes 
Unfortunately, existing antiviral therapies such as glucocorticoids 
and immunoglobulin therapy cannot significantly increase the chances 
of survival of patients with severe COVID-19. One successful strategy is 
using convalescent plasma from patients recovered from a viral infection 
without severe adverse events [130,131]. On the other hand and given 
the importance of cytokine storm and inflammation-mediated lympho-
penia in the pathogenesis of COVID-19, especially in severe cases, there 
are endorsed attempts to design new therapeutic strategies that are 
intended to control these events. 
5.1. Blockade of pro-inflammatory cytokines 
Once SARS-CoV-2 binds to TLRs, a cascade of events is stimulated 
within the cells resulting in the production of pro-inflammatory cyto-
kines, such as IL-1β and IL-6. The results of several studies revealed that 
over-secretion of these cytokines are responsible for the dysfunction of 
the lungs and the emergence of systemic clinical symptoms. Interest-
ingly, when Zhao et al. evaluated the therapeutic potential of Tocilizu-
mab, a specific monoclonal antibody against IL-6, they found that the 
agent was successful in reducing the lung lesion opacity of severe cases 
of COVID-19 patients. Notably, administration of Tocilizumab could 
also increase the number of peripheral lymphocytes; further high-
lighting the importance of inflammation-mediated lymphopenia in 
COVID-19 [3]. Sarilumab, an IL6 blocker, also showed significant effects 
in severe cases of COVID-19 [132]. Apart from IL6 blockage, it seems 
that IL1 family suppression could bring advantages for COVID-19 pa-
tients. The blockage of IL1β by using IL37, an inhibitor of MHC-II, may 
bring a ray of hope for COVID-19 patients. IL38 is another inhibitory 
cytokine that has the ability to inhibit IL1β and other members of the IL1 
family caused by SARS-CoV-2 [133]. Taken together, these results sug-
gested that inhibition of inflammatory cytokine may help us to control 
inflammation-induced complications, such as lymphopenia in COVID- 
19. 
TNF-α is notorious in inflammatory diseases due to its ability to 
induce apoptotic cell death in aged T lymphocytes by interacting with its 
receptor named TNFR [134]. Since TNF-α accounts for lymphopenia in 
viral infections, it is not surprising that anti-TNF-based therapies have 
found their ways into the clinic to treat a wide range of viral infections, 
such as COVID-19. Accordingly, it became evident that anti-TNF treat-
ment could provide a significant outcome in animal models that mimic 
lung viral infection in humans [54]. Among the long list of drugs queued 
as TNF inhibitors, only a few such as infliximab or adalimumab received 
the approval to be used for reducing the inflammatory responses in 
COVID-19 [134]. Overall, it seems that anti-TNF treatment may be 
beneficial if they are administrated at the early stage of the disease. 
5.2. JAK inhibitors 
The JAK/STAT pathway is one of the common signaling axes that is 
recruiting by both SARS-CoV-2 host cells and immune cells to transmit 
their desired messages to the nucleus [135]. Given this, it seems if this 
pathway is inhibited, an order of unnecessary cytokine production 
would be interrupted. The superiority of JAK inhibitors to other 
immunomodulatory agents has been proposed to be attributed to their 
ability to exert dual anti-inflammatory and anti-viral properties. The 
favorable pharmaceutical characteristics such as oral administration 
and short half-life are also other advantages of these inhibitors [136]. 
One of the JAK inhibitors that received its approval from the FDA is 
Fedratinib; an agent with a significant ability to suppress inflammation 
by reducing the secretion of IL17 and IL22 from murine Th17 cells. Since 
COVID-19-mediated inflammation is characterized by Th17 cytokine 
signature such as what is happened in MERS-CoV cases, so administra-
tion of Fedratinib may be beneficial in the treatment of COVID-19 via 
suppression of Th17-associated cytokine storm [137]. In addition to 
Fedratinib, Baricitinib and ruxolitinib are other potent and selective JAK 
inhibitors. Stebbing et al. introduced Baricitinib as a promising agent in 
the treatment of COVID-19 due to its safety profile and high efficacy. 
Notably, the results of this study showed that abrogation of the JAK axis 
could block the entry of viruses into host cells and prevent the propa-
gation of inflammatory responses [138]. The combinational strategies 
consisting of Baricitinib and conventional anti-viral agents such as 
lopinavir, ritonavir, or remdesivir may also be fruitful for patients 
infected with SARS-CoV-2 [138]. Accordingly, the administration of 
Ruxolitinib was successful to prevent multiple organ failure in COVID- 
19 patients with hyper-inflammation [139]; further highlighting the 
importance of JAK inhibition in the management of patients with 
COVID-19, especially those with systemic involvement. 
5.3. Complement inhibitors 
Having established that complement stimulation may have a role in 
the pathogenesis of COVID-19, it is postulated that if complement in-
hibitors are used at the initiating stage of the disease, they would bring 
fortune for patients, especially those who need more intensive treat-
ments [24]. Mastaglio et al. claimed that C3 inhibition using AMY-101 
could attenuate the tissue’s destructive inflammatory responses and 
serve as a safe therapeutic option for COVID-19 patients with systemic 
hyper-inflammation [140]. Other critical members of the complement 
cascade that may also have a role in COVID-19–associated tissue in-
flammatory injury are C5a and C5b. The efficacy of anti-C5aR mono-
clonal antibody, avdoralimab, in severe cases of COVID-19 patients has 
been tested in a double-blind randomized study [141]. Moreover, Stahel 
et al. shed light on the advantageous effect of targeting complement 
components in COVID-19 patients and suggested that this therapeutic 
approach could prolong the survival of younger patients that had 
symptoms of hyper-inflammation, thromboembolic complications, and 
cardiac arrest [142]. Although therapeutic approaches intervening in 
the activation of complement seem to be effective, it should not be 
forgotten to be cautious in the administration of such agents to avoid any 
unfavorable harmful side effects. 
5.4. Immunomodulators 
The idea behind the application of immunomodulators in the ther-
apeutic approaches of COVID-19 patients is stemmed from the success of 
pegylated IFNα-2a and 2b immunomodulators in the treatment of hep-
atitis B and C infections [143]. Through provoking anti-viral innate 
immune responses against SARS-CoV-2, immunomodulators seem to be 
successful in eliminating the number of pathogens in patients. A clinical 
trial is currently underway to examine the effect of combination therapy 
of ribavirin and pegylated interferon in patients with COVID-19 
(ChiCTR2000029387). Other immunomodulators such as Pseudo-
monas aeruginosa and thymosin also showed befitting results in the 
treatment of COVID-19 patients; however, their efficacy and safety 
should be evaluated through more precise investigations [31]. 
5.5. MSC therapy 
The beneficial impact of mesenchymal stem cells (MSCs) for COVID- 
19 patients is not only due to its regenerative effects in impairing tissue 
injuries but also is for its influential anti-inflammatory and immune- 
modulatory properties [144]. Z. Leng et al. conducted a study on 
seven severe COVID-19 patients who were subjected to 1 × 106 MSCs/ 
kg. After infusion of MSCs, while there was a significant elevation in the 
number of peripheral lymphocytes, the serum levels of TNF-α and CRP 
were dropped down remarkably [76]. Choudhery et al. also reported the 
success of MSC transplantation in diminishing the level of TNF-α as well 
as elevating the serum level of IL-10 in critical cases of COVID-19 [145]. 
Incidentally, Rajarshia et al. [146] and Golchin et al. [147] found that 
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Table 2 
A list of clinical trials investigating the efficacies of therapeutic approaches in COVID-19.   
Drug Mechanism Population/Severity No. Phase Status Aim and outcome Identifier 
Targeting specific inflammatory molecules & pathways  




A multicenter, randomized, double-blind, 
placebo-controlled study to assess the efficacy 
and safety of canakinumab-plus-SOC compared 
with placebo-plus-SOC. 
NCT04362813  
Anakinra IL-1R antagonist COVID-19 patients. 180 Phase 
2/3 
Recruiting A randomized, parallel group, 2-arm study, 
investigating the efficacy and safety of anakinra 
added to standard treatment, compared to 
standard treatment alone. 
NCT04443881  
Sarilumab mAb against IL-6 COVID-19 patients 






A randomized controlled trial to determine the 
therapeutic effect and tolerance of Sarilumab in 
COVID-19 patients. 
NCT04324073  





Completed A randomized controlled trial to evaluate the 
effect of Tocilizumab on multi-organ 
dysfunction among hospitalized COVID-19 
patients. 
NCT04356937  
Situximab IL-6 neutralization COVID-19 patients 
with acute respiratory 






To evaluate safety and effectiveness of 
individually or simultaneously blocking of IL-6 
and IL-1 versus standard of care on blood 
oxygenation and systemic CRS. 
NCT04330638  
Infliximab TNF α blocker COVID-19 patients 




Recruiting A single center trial to assess the efficacy of 
infliximab or infliximab-abda in hospitalized 
COVID-19 patients. 
NCT04425538  
Baricitinib Jak inhibition COVID-19 patients. 1400 Phase 
3 
Recruiting To evaluate the efficacy of baricitinib in 
hospitalized COVID-19. 
NCT04421027  
Emapalumab INF II blocker COVID-19 patients. 16 Phase 
2 
Terminated To reduce the number of patients requiring 
mechanical ventilation, and to address the most 
urgent need to preserve the access to ICU 
support to the lowest possible number of 
patients. 
NCT04324021  
Inhibition of complement activation  
Eculizumab C5 Inhibitor ICU-admitted COVID- 
19 patients with 
ARDS. 
N/A N/A Available To evaluate if mortality can be halted while the 
patient has time to recover from the virus. 
NCT04288713  






To assess both the efficacy and safety, as well as 
pharmacokinetics and pharmacodynamics of 
C3 inhibition in COVID-19. 
NCT04395456  
Avdoralimab C5aR Antibody COVID-19 patients 
with severe 
pneumonia and ARDS. 
168 Phase 
2 
Recruiting To reduce the need for and duration of 
mechanical ventilation in patients with COVID- 
19 pneumonia ARDS. 
NCT04371367  
Immunomodulators  
HCQ increases lysosomal 
pH in APCs 
COVID-19 patients. 58 Phase 
2 
Terminated A randomized, blinded trial to confirm or refute 
the efficacy of HCQ in early treatment of 
COVID-19 to reduce viral load. 
NCT04353271  
p-IFN lambda Anti-viral activity COVID-19 patients 




Recruiting To assess safety and tolerability of Lambda by 
adverse event monitoring, and vital signs 
assessment. 
NCT04534673  
MSC therapy  
MSCs Immunomodulation COVID-19 patients 




Recruiting To assess the efficacy of MSCs as an add-on 
therapy to standard supportive treatment for 
COVID-19 patients. 
NCT04444271  




Recruiting To investigate the potential use of WJ-MSCs for 
treatment of patient diagnosed with COVID-9. 
NCT04313322  
NestaCell® Immunomodulation COVID-19 patients 





To assess the efficacy of NestCell® as an add-on 
therapy to standard treatment to treat patients 
with COVID-19 pneumonia. 
NCT04315987  
Modulation of lymphocyte exhaustion  
Nivolumab PD-1 blockade COVID-19 patients 





To evaluate the efficacy of nivolumab in 
combination with standard treatments. 
NCT04343144  
Pembrolizumab PD-1 blockade COVID-19 patients. 24 Phase 
2 
Recruiting To assess the efficacy of continued standard 
care together with tocilizumab plus 
pembrolizumab. 
NCT04335305  
NK cell-based therapy  







To evaluate the safety and immunogenicity of 
allogeneic NK cells from PBMCs of healthy 
donors in patients with COVID-19. 
NCT04344548  











To evaluate the safety and efficacy of multiple 
doses of CYNK-001. 
A randomized, open-label design of multiple 
doses of CYNK-001 compared to the control. 
NCT04365101  
Novocellbio Memory T and NK 
cells cytotoxicity 
COVID-19 patients 
with worse prognosis. 
58 Phase 
1/2 
Recruiting A randomized escalating-dose trial to 
determine safety, alloreactivity, and efficacy of 
NCT04578210 
(continued on next page) 
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MSCs may be possibly one of the most ideal therapeutics, or considered 
as a combinational treatment for COVID-19 patients. It has been also 
reported that allogeneic bone marrow MSC-derived exosomes are 
enabled to reduce cytokine storm, restore oxygenation, and reconstruct 
the immune responses in the favor of the COVID-19 patients’ survival 
[145]. All in all, the evidence supports the effectiveness of MSC products 
in the treatment of COVID-19 patients, as they may reduce pro- 
inflammatory cytokines and improve lymphopenia-related 
complications. 
5.6. Modulation of lymphocyte exhaustion 
Induction of lymphocyte exhaustion holds a respectable share in the 
pathogenesis of viral diseases and COVID-19 is not an exception. Given 
this, strategies that block PD-1/PD-1L and TIM3 appear to be effective in 
preventing lymphopenia or lymphocyte dysfunction in viral infections. 
So far, several monoclonal antibodies (mAbs) against PD-1 or NKG2A 
are designed to restore the cytotoxic phenotype to T and NK cells and 
facilitate the elimination of the virus [47,148]. Given the results of a 
study showing that increased absolute lymphocyte count and decreased 
absolute neutrophil count levels during nivolumab therapy correlated 
with a better response in melanoma [149], it is reasonable to assume 
that anti-PD-1 antibodies such as nivolumab or pembrolizumab may act 
as promising candidates for the treatment of lymphopenia in patients 
with COVID-19. 
Table 2 (continued )  
Drug Mechanism Population/Severity No. Phase Status Aim and outcome Identifier 
adoptive cell therapy of NK cells or memory T 
cells. 
NK: Natural Killer; PBMCs: Peripheral blood mononuclear cells; CYNK-001: CYNKCOVID; ARDS: Acute respiratory distress syndrome; PD-1: Programmed cell death- 
1; SOC: Standard-of-care; CRS: cytokine release syndrome; IL-1: Interleukin-1; HCQ: Hydroxychloroquine; p-IFN: Pegylated Interferon Lambda; WJ-MSCs: Wharton’s 
Jelly-Mesenchymal Stem Cells; APC: Antigen-presenting cell. 
Fig. 4. The brief story behind the inhibitory effects of SARS-CoV-2 on lymphocytes. By entering SARS-CoV-2 into the body, a group of events takes place to have 
destructive effects on lymphocytes. Elevation in TH1 cells and abnormal aggregation of extra-follicular TNF-α could hamper differentiation of Bcl-6+ T follicular 
helper cells (TFH), an event which in turn results in decreased formation of germinal centers and disturbed humoral immune responses. On the other hand, un-
restrained production of inflammatory cytokines is triggered during COVID-19 and leads to aberrant systemic inflammatory responses, which in turn, may induce 
exhausted phenotype in T cells. SARS-CoV-2 also affects NK cells and makes them inefficient. All the above-mentioned events go hand in hand to exacerbate COVID- 
19 via induction of lymphopenia and dysfunctional lymphocytes. 
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5.7. NK cell-based therapy 
The lower number of circulating NK cells in SARS-CoV-2 infected 
patients has fired up an idea of application of the NK cell-based therapies 
as a weapon to combat the disease through boosting the host immune 
system’s function [150]. Recently, the FDA permitted Cellularity to 
evaluate the therapeutic value of a universal NK cell therapy CYNK-001 
named NKG2D-ACE2 CAR-NK cell therapy in COVID-19 patients [151]. 
Not only this approach was doing well in eliminating virus-infected cells 
also it could prevent the ability of SARS-CoV-2 in infecting the suscep-
tible cells, such as alveolar epithelial cells. In the middle of 2020, 
autologous NK cell treatment agent “Novo-NK” has achieved a break-
through in the treatment of COVID-19 patients, as it could rapidly 
remove a considerable proportion of viruses [152]. Odabasi et al. 
revealed that suppression of NKG2A receptors could be used as an 
approach to reinforce the antiviral activity of cytotoxic T cells and NK 
cells, resulting in the elevation of absolute lymphocyte count. They also 
suggested that the synergistic effect of NKG2A inhibitor (as an immune 
system booster) with IL-6R antibody (as an anti-inflammatory agent) 
could bring a ray of hope for the severe cases of COVID-19 patients 
[153]. Although it is early to hazard a conclusion, it seems that the 
combination of NK cell-based therapy and standard therapy may provide 
outstanding results in COVID-19. A list of clinical trials summarizing all 
these approaches was presented in Table 2. 
6. Conclusion 
With the massive numbers of studies that scrutinize the biology of 
SARS-CoV-2, now, the basic knowledge about the virus is to the degree 
that several therapeutic approaches have been designated for the dis-
ease; however, still there are several questions that need to be answered. 
By putting the current knowledge together, we can step toward diag-
nosis, prognosis, and treatment of the COVID-19 infection at an early 
stage. By direct damage to lymphatic organs and also by increasing the 
release of sCD25, it seems that not only SARS-CoV-2 diminishes the 
number of host’s lymphocytes but also induces exhaustion phenotype in 
effector T cells and NK cells; an event which in turn paralyzes the im-
mune system and may result in overproduction of pro-inflammatory 
cytokines in a compensatory manner. Reciprocally, the emergence of 
cytokine storm may exacerbate both lymphopenia and induction of 
exhausted lymphocytes (Fig. 4). Given this, it is reasonable to assume 
that any treatment strategy that targets lymphopenia __either directly or 
indirectly__ would bring advantages for COVID-19 patients. So far, many 
of these approaches, including inhibition of inflammation and 
enhancing lymphocytes have been tested on COVID-19 patients; how-
ever, to ensure the efficacy and the safety profile of these treatments, 
more clinical investigations are required. 
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M. Lafarga, M.J. Cortti, A. Lazaro-Garcia, R. Pérez-Tanoira, Á. Trascasa, 
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